California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
ATLANTA, Nov. 09, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen’s CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at 2:15pm ET in New York.
A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.aviragentherapeutics.com or at http://wsw.com/webcast/stifel5/avir.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
